The MyCode Community Health Initiative (MyCode) is returning actionable results from whole exome sequencing. Familial hypercholesterolemia (FH) is an inherited condition characterized by premature cardiovascular disease.
H ypercholesterolemia affects 71 million (30%) adults in the United States. 1 Of these, some have unidentified familial hypercholesterolemia (FH). FH is an autosomal dominant disorder causing significant lifelong elevations in LDL-C (low-density lipoprotein cholesterol), which results in increased risk of early-onset heart attacks and strokes. [2] [3] [4] [5] [6] Discriminating multifactorial hypercholesterolemia from FH can be difficult in practice because of significant overlap in clinical presentation. Specific FH diagnostic tools (Dutch Lipid Clinic Criteria, Simon Broome Diagnostic Criteria, and Make Early Diagnosis to Prevent Early Deaths) and genetic testing for FH genetic risk results (LDLR, APOB, and PCSK9) can help identify individuals 7 ; despite that, currently, only ≈10% of FH affected individuals are aware of their diagnosis. 2, 8, 9 Increased efforts to identify individuals with FH have revealed that the prevalence of FH has been underestimated, with estimates increasing from 1:500 10 to 1:200 11 to 1:222. 12 Unrecognized FH leads to undertreatment and inadequate disease control. Lipid-lowering therapy (LLT) with statins are recommended as first line therapy for individuals with FH by the American Heart Association and National Lipid Association FH guidelines. 7, [13] [14] [15] The National Lipid Association 2015 Recommendations for PatientCentered Management of Dyslipidemia and National Lipid Association FH guidelines recommend treating individuals to specific LDL-C treatment goals: LDL-C <100 mg/dL or LDL-C <70 mg/dL with the presence of cardiovascular disease (CVD) or other risk factors. 7, 16, 17 Often, statin monotherapy in individuals with FH will not reduce LDL-C to recommended goals. Therefore, combination therapy with additional LLTs, such as ezetimibe, bile acid sequestrants, niacin, or PCSK9i (proprotein convertase subtilisin/ kexin type 9 inhibitors), is required. However, it is estimated that only 50% of individuals with FH receive treatment with any LLT, 11 and a study conducted in the Netherlands reported only 21% of patients with FH achieved their LDL-C goal when prescribed LLT. 18 Thus, identifying FH is important to ensure adequate medication management to obtain disease management recommendations.
As genetic screening becomes more common for identification of FH individuals, 12 it would be beneficial to better understand patients' perceptions of this information and how this impacts the way in which they manage their health. The most common method of learning genetic test results often come from targeted testing initiatives, such as consulting with a healthcare provider after having an unexplained event (eg, heart attack) or learning about a genetic condition from a family member. Literature exists regarding an individuals' perceptions of genetic testing for FH from targeted initiatives and its influence on disease management, including awareness of CVD risk and influence on medication adherence. 19 Some individuals have regarded genetic testing as an unexceptional event to them; however, they valued the ability to impart this knowledge to other family members. 20 A genetic testing initiative in the Netherlands based on cascade testing (targeted initiative) of at risk family members for FH found that individuals perceived their CVD risk to be low, yet reported high medication adherence. 21 Others have reported that individuals knowing that they have a higher risk because of a personal history of CVD were more likely to be adherent to LLTs. 22 Despite these insights, we are unaware of any literature to date that explores individuals' perceptions and barriers to care, or how care is delivered, after receiving an incidental test result for FH as part of a population genomic screening initiative. In 2008, Geisinger launched its MyCode Community Health Initiative (MyCode). 23 Any Geisinger individual is eligible to participate and is consented during an office visit or through MyGeisinger, an electronic patient portal. Blood or tissue samples are collected during routine clinical care visits and whole exome sequenced. Individuals who consent agree to be recontacted for future studies. Based on return of 76 clinically actionable genes, ≈3.5% of individuals within the Geisinger population can expect results and this number will increase over time as new genes are added. 24 Thus, Geisinger is uniquely positioned to understand the impact on disease management and care patients seek after learning they have a genetic DNA variant for FH from a population screening initiative rather than a disease manifestation perspective.
METHODS
The methods section is available in the Data Supplement (includes interview guides and demographic survey). The authors declare that all supporting data are available within the article and in the Data Supplement. This study was approved by the Geisinger Institutional Review Board.
RESULTS
At the time this study was conducted, 28 individuals had received a pathogenic or likely pathogenic variant in LDLR or APOB. Of those, 23 individuals met inclusion criteria and 7 individuals consented to participate in semistructured interviews.
In the study sample of individuals, who received FH genetic test result from MyCode and had a Geisinger primary care provider, 13 individuals (57% of 23) received an LDLR variant and 10 individuals (43% of 23) received an APOB variant (Variant List; Table I in the Data Supplement). Two of the individuals were half siblings (both with the same LDLR variant) and 2 of the individuals were first cousins (both with the same LDLR variant). Based on chart review, 15 individuals (65% of 23) in the cohort were female and the median age of 66 years (range, 27-85). Median length of follow-up time was 1.32 years (range, 0.9-1.9) from receiving the FH genetic test result to the end of the study period. Conditions noted in patient problem lists ( Table 2 ). One individual had their first LDL-C recorded in the electronic health record (EHR) after learning their result, and this was recorded as their highest LDL-C value (142 mg/dL).
Healthcare Follow-Up After Learning a FH Genetic Test Result
Nineteen individuals (80% of 23) had documentation that the FH genetic test result was discussed with a healthcare professional ( Figure) . Documentation in the EHR of follow-up with a healthcare professional was unavailable for 4 individuals. Eight individuals (42% of 19) discussed this specific genetic result with clinical genomics specialist (either a geneticist or genetic counselor); 5 individuals discussed with their primary care provider (26% of 19), 3 with a cardiologist (16% of 19) , and 3 with a pharmacist (16% of 19) . No difference in medication use or LDL-C was present, after result disclosure in 4 individuals.
Medication Use After Learning a FH Genetic Test Result
After learning their results, 9 individuals (39% of 23) had changes made to their treatment regimens, including 4 individuals (44% of 9) had increases in statin intensity or dose, 4 individuals (44% of 9) were prescribed an additional LLT, and 1 individual (11% of 9) was initiated on new therapy (Statin potency and intensity; Table II in the Data Supplement). Four individuals that had a previous clinical diagnosis of FH (80% of 5) had changes made to their medication regimens. Overall, 18 individuals (78% of 23) were prescribed LLTs and of those 8 individuals (44% of 18) were prescribed at least 2 LLTs (Table 2) . Of these individuals, 12 individuals (67% of 18) prescribed highintensity statins and 4 of them were prescribed at least 1 additional LLT. Four individuals were prescribed moderateintensity statin with 2 individuals prescribed combination therapy. Two individuals were prescribed PCSK9i; 1 continued their high-intensity statin and the other was prescribed a bile acid sequestrant as an additional agent.
Six individuals (26% of 23) had a history of statin allergy documented in the allergy section of the EHR (Table 2) . Allergies listed included simvastatin, pravastatin, atorvastatin, rosuvastatin, and statins. Despite documentation of statin allergies, 4 individuals were prescribed LLT, including statins while 2 were untreated. Of the 4 treated individuals, prescribed therapy after receiving the genetic test result included PCSK9i, high-intensity statins (2), and moderate-intensity statins (Table 2) .
Disease Control After Learning a FH Genetic Test Result
Before result return, 22 individuals (96% of 23) had LDL-C documented in the EHR with a median of 136.5 mg/dL (range, 61-383) and were drawn a median of 148 days (range, 6-542) after. Nineteen individuals had at least 1 LDL-C drawn after learning their result and on average, these individuals had their LDL-Cs checked 1.9× (SD=0.91) over the course of 1.32 years (range, 0.9-1.9). After learning their result, the median first LDL-C drawn was 132 mg/dL (range, 83-289) with a median length of time of 131 days (range, ).
Based on current FH guidelines, disease control would be achieved when individuals met specific LDL-C treatment goals: LDL-C <100 mg/dL or LDL-C <70 mg/ dL with the presence of CVD or other risk factors. At the time of the interview, 5 individuals reported a personal history of high cholesterol, heart attack, or heart disease and almost all these individuals (6, 68% of 7) knew about their family history of high cholesterol or heart disease. Two individuals felt learning about their genetic result provided an answer. Three were not surprised; and of those 3, 2 reported that learning this did not trouble them. All individuals reported that they felt treated for their high cholesterol currently. Three individuals described current medications they were prescribed and 1 discussed that their doctor recently prescribed another medication. When prompted about barriers to receiving care, only 1 individual explained how high cost of medications was a barrier to receiving and adhering to her treatment plan. Only 3 individuals talked about using diet and exercise to control their high cholesterol.
"Well I'm on top of it as much as I can be. And it doesn't frighten me. And it doesn't cause me any stress." (female participant a) "No, because I'm on the highest doses on just about everything you could be, I've had a little bit of side effects from some things. … I'm on four meds, so therefore he didn't have anything to adjust." (female participant b)
As part of the MyCode process, all genetic test results are first returned to a patient's primary care provider of record and then a week later to the patient by a MyCode team member. 25 Five individuals (of 7) interviewed reported discussing this result with their primary care provider, while 1 followed up with clinical genomics and cardiology and 1 with cardiology. One individual that was later referred to cardiology reported a triple bypass surgery as a result of acting on the result.
After discussing the result with their clinician of choice, 5 individuals (71% of 7) discussed certain concepts that reflected an understanding of FH. Two individuals expressed how they knew their LDL-C could not be lowered by diet alone, whereas others (2, 29% of 7) were concerned about their increased risk for heart attacks. Only 1 spoke about the inherited nature of FH. Two individuals were able to relate the importance of this result for family members. Although 5 offered these thoughts highlighting at least a partial understanding of the FH diagnosis, 1 individual explicitly expressed confusion and uncertainty for future medical care.
"But when I go back to [my PCP] I'd like to know how often now I'll have my cholesterol checked. You would think at least two times a year, at least once a year. So that I don't know. And like I said, I don't know if I should stick with the cardiologist or just deal…but I mean, I probably should stick with the cardiologist, I mean that only does make sense. So no one told me you have to stay with, you know you have a cardiologist or whatever, I don't know." (female participant c)
One individual described how learning this result prompted her to ask her mother about their family history of heart disease. As a result of this outreach she discovered nonpaternity (that the person she believed to be her father was not in fact her biological father).
She describes her discovery as "I mean, yes it shocked me and everything, but I wasn't like crying and upset ..." (female participant c).

DISCUSSION
We aimed to describe and understand healthcare utilization and patient perspective after receipt of a pathogenic or likely pathogenic variant in LDLR, APOB, or PCSK9 from a population-based biobank. We found most individuals discussed this genetic test result with a healthcare provider but only few had changes to their treatment plans as a result of the genetic information. Most individuals in our study were already receiving treatment for high cholesterol and either continued or increased the intensity of treatment after learning their FH genetic test result, however, most remain uncontrolled for their disease. Patients reported that learning this result was not surprising and important to know but felt that they were already being treated for their high cholesterol, so no further action was needed. Thus, leading us to think a disconnect in understanding exists between having a diagnosis of high cholesterol and FH.
Our treatment utilization of 78% is similar to previously reported treatment utilization from 53% 26 to 84.7% 27 in individuals with FH. Similar to other studies, 26, 27 we found in our study that despite treatment with LLTs, that most individuals were not at goal. Within our population of individuals with a FH genetic risk result, we identified several commonly occurring comorbidities. Our study found that these individuals had a high prevalence of hypertension (48%) compared with 29% in the US population, 28 which is similar to previous work in the CASCADE-FH Registry (43%). 29 The significance of this finding is unknown and future work is needed to confirm and further explore this finding. The prevalence of type 1 (4%) and type 2 (9%) diabetes mellitus in our population is similar to the US population (6.5%). 30 In a previous study from data from the CASCADE-FH Registry of individuals with FH reported a similar prevalence of diabetes mellitus (13%). 29 We saw similar rates of obesity (26%) as the CASCADE-FH Registry. 29 Thirty-five percent of individuals in our study had a problem list diagnosis of stage III chronic kidney disease but it is unknown the significance of this result. Future work should be conducted to understand the influence of comorbid conditions on individuals with FH.
Previous studies examining patient perspective about genetic testing from target screening initiatives found that individuals about this information as nonsurprising but important for their family members. 20, 21, [31] [32] [33] Additionally, it has been reported that patients and clinicians lack of understanding about the differences between FH and high cholesterol diagnosis. 20, 21, [31] [32] [33] Our study found that individuals reported similar perspective, even after receiving their genetic test results from a populationbased genomic screening initiative. In our study, individuals described that they already knew they had high cholesterol and felt treated. These assumptions about feeling treated might explain why they underestimate their CVD risk in general, which has also been previously demonstrated. 21, 31 Most noted they were aware of their family history and that this result provided them with knowledge about their condition. 20 These attitudes expressed by individuals may explain why minimal changes have been made to their medication regimens and why the majority were not at their LDL-C treatment goal. Most individuals did discuss this formal FH diagnosis with their healthcare providers, but not all. It is possible that ineffective communication between the study team, healthcare professionals, and individuals may account for the potential nonurgency seen when these results were received, and lack of reaching LDL-C goals.
Some unexpected results emerged from this study. Surprisingly, in our initial cohort of FH genetic test returned, we have a high number of individuals with APOB variants (43%) and none of these individuals were related. APOB variants account for 1% to 5% of FH variants, whereas 60% to 80% are LDLR variants. In a previously published study of a 50 000 person FH cohort from MyCode, of which the cohort in this study is a subset, we found that 40% (92/229) individuals had a APOB variants but at the time of this study not all these results have been returned. 12 All of the APOB variants returned in this study, were missense variants (c.10580G>A) which is the most common APOB variant, 34 and is especially prevalent in the Amish population. 35 Geisinger is located in central Pennsylvania where the Pennsylvania Dutch settled, with a large Amish and Mennonite population. The delay in healthcare utilization was shocking, that there was an average lag time of 148 days (range, 6-542) from time of genetic result return to draw of LDL-C. Five individuals had been diagnosis clinically with FH before learning their genetic test result. As part of our chart review protocol, we did not collect information on if these individuals had changes made to improve intensity of their treatment when learning of their clinical diagnosis, but it is interesting to note that 4 of them did make changes to their medication regimens after learning about a genetic test result for FH. In addition, none of the 5 indi- In the field of cardiology, it is unlikely to return laboratory tests that result in the discovery of nonpaternity, however, this is not an unexpected outcome in the field of genetics. This outcome seen in our study is 1 potential risk of returning genetic test results, but there are also many benefits associated with genetic testing. Previously published studies showed that not all FH variant carriers would have been identified by clinical ascertainment. 12, 36 Identification of a proband either by genetic or clinical testing can promote cascade testing of family members. 37 Our data indicates that clinicians are not treating FH as aggressively as recommended by guidelines and the reason for this is unknown. The responsibility of managing this result does not lie solely with the patient but with the individuals' healthcare providers alike. This study found that, even after learning these results, clinicians were not necessarily making changes to individuals' medication regimens. Even though, supportive materials describing guideline-recommended treatment strategies for FH are provided to clinicians and patients as part of MyCode. Future research should be conducted to understand the reasons clinicians did not make changes to an individuals' treatment plan after the FH genetic risk result was known. Various potential solutions exist to help reduce the knowledge gap experienced by clinicians and patients about FH. Directive messaging about the importance of discussing this result with a lipid specialist and a cardiovascular genetic counselor could be suggested at time of result return. Other solutions include development of a risk communication tool that can be used by clinicians with patients or patients with family members to discuss the importance of this result.
Limitations
This study was an exploratory analysis in a small sample of individuals who had received a FH genetic test result incidentally to their participation in a biobank. Because of this small sample size statistical analysis would not be meaningful. The population studied may not be representative of other FH populations because of the older and containing only genetically identified cohort. The FH cohort described here, was older than the general MyCode or Geisinger cohort. This could reflect a survival bias in these individuals as this condition often results in early-onset CVD, which these individuals have been able to outlive. Furthermore, these individuals may be less motivated to act on their FH genetic test result because of other comorbid conditions affecting their health. Finally, we chose not to link patients who consented to share their experience in the interviews to their EHR data to provide anonymity.
Conclusions
Results from this pilot study are based on data from 28 individuals identified with FH genetic risk results as part of a population genomic screening initiative. Despite learning their positive genetic screening for FH, only 5 individuals had met the aggressive LDL-C goal for FH and only 1 individual of 6 that were not previously prescribed LLT was initiated on therapy. For those individuals that had previously been treated for hypercholesterolemia, about half had increases in the intensity of their LLT. Interviews with individuals revealed limited knowledge or understanding that their new FH diagnosis was different their previous hypercholesterolemia diagnosis. Results from this study will be used to iterate on and improve on our current clinical results reporting and follow-up process with the goal of transforming the conversation about FH care with individuals and clinicians alike.
Further study is needed on how to optimize communication of FH risk and treatment goals to patients and clinicians in the setting of genetic screening.
